An Open-Label, Dose Titration Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046, A Sustained-Release Analogue of Vasoactive Intestinal Peptide, In Adult Subjects With Pulmonary Arterial Hypertension
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2018
At a glance
- Drugs PB 1046 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors PhaseBio Pharmaceuticals
- 18 Dec 2018 Planned End Date changed from 1 Nov 2018 to 1 Jan 2019.
- 18 Dec 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Jan 2019.
- 04 Sep 2018 Planned End Date changed from 1 Sep 2018 to 1 Nov 2018.